Tailoring the treatment of acute myeloid leukemia

Burnett, Alan 1999. Tailoring the treatment of acute myeloid leukemia. Current Opinion in Hematology 6 (4) , pp. 247-252.

Full text not available from this repository.

Abstract

For younger patients with acute myeloid leukemia, the current priority is to prevent disease relapse. Intensification of induction has been shown to achieve this. Several randomized trials have been conducted to evaluate the role of autografting in acute myeloid leukemia. All trials reduce the risk of relapse but do not necessarily improve the survival, either because the competing effects of procedural mortality or salvage after relapse balance the benefits. Patients with different risk profiles may have different treatment plans. In older patients, progress is difficult to detect. Overcoming inherent drug resistance is of current interest, while improving supportive care by the routine use of growth factors has been disappointing.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher:	Lippincott, Williams & Wilkins
ISSN:	1065-6251
Last Modified:	25 Jun 2017 05:12
URI:	https://orca.cardiff.ac.uk/id/eprint/70338

Citation Data

Cited 14 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item